News
Superior survival with sintilimab in squamous NSCLC
Sintilimab improved overall and progression-free survival, when compared with docetaxel.
News
Tislelizumab bests docetaxel in NSCLC
Tislelizumab was associated with better outcomes in patients with locally advanced or metastatic non–small cell lung cancer.
News
Antibiotics may prolong PFS in HCC patients on immunotherapy
Prior studies suggested that antibiotics reduce the efficacy of immunotherapy.
News
Tebentafusp improves OS: A first in metastatic uveal melanoma
Tebentafusp prolonged overall survival by nearly 6 months.
News
Personalized cancer vaccine shows early promise across tumor types
The vaccine consists of patient-specific synthetic neoantigen peptides and is given to patients in the adjuvant setting.
News
Healthy lifestyle may offset genetic risk in prostate cancer
In men at the highest risk of dying from prostate cancer, a healthy lifestyle cut the risk of fatal disease in half.
News
Black nonsmokers still at high risk for secondhand smoke exposure
The prevalence of SHS exposure among nonsmokers declined from 87.5% to 25.3% between 1988 and 2012.
News
Is the WHO’s HPV vaccination target within reach?
The WHO’s goal is to have HPV vaccines delivered to 90% of all adolescent girls by 2030.
News
Routine vaccinations missed by older adults during pandemic
Another drop in the rates of adult vaccinations may have occurred due to the surge in COVID-19 infections in the fall of 2020.
News
COVID-19: Peginterferon lambda may prevent clinical deterioration, shorten viral shedding
Activity against respiratory pathogens has been demonstrated for interferon lambda-1, a type III interferon.
News
Many ED visits may be preventable for NSCLC patients
Overall, 24% of ED visits were deemed preventable, and 10% were considered unnecessary.
News
Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases
Findings could lead to better monitoring of comorbidities and deeper understanding of disease burden and AD pathophysiology, the authors write.
News
Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy
Delayed count recovery remains a key safety concern.